SecBot SecBot

PRME

Prime Medicine, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001894562 Biotech & Drug Discovery
$4.28 +0.67 (+18.42%)
Oct 27 4:00 PM ET · prev $3.61
Market cap
$665.7M
Small cap
Consensus
Buy
80% Buy or better · 20 analysts
Median target
$7.00
+64% · range $4.25–11.00
Next earnings
Oct 30
in 3 days · EPS est. −$0.23
1 year
−17.0%
from $5.15 · Oct 27
30 days
+48.7%
from $2.88
52-week range
$2.70–5.15
−17% from high · low May 19
Avg volume 20D
5.12M
shares / day
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Reddit crowd
60°
Warm · 1 mention this week
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 2 bullish oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Oct 30, 2026
Strongest BULLISH Prime Medicine announced FDA clearance of its IND application for PM647, an in vivo Prime Editor for Alpha-1…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 19 added (0 new), 13 trimmed or exited.

  • AnalystsBULLISH

    16 of 20 rate it Buy or better. Median target $7.00 (+64%).

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.227 → −$0.234 over 90 days. 1 up, 1 down in 30 days.

  • TrendUPTREND

    25% above its 50-day average.

  • SocialQUIET

    Crowd 60° (warm) this week from 1 mention: 1 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ARK Investment Management LLCADD8,348,746$30.8M
GOLDMAN SACHS GROUP INCDOUBLED3,430,518$12.7M
CITADEL ADVISORS LLCDOUBLED2,054,543$7.6M
BANK OF AMERICA CORP /DE/ADD981,335$3.6M
D. E. Shaw & Co., Inc.TRIM648,940$2.4M
MARSHALL WACE, LLPADD216,841$800.1K
CITIGROUP INCDOUBLED195,664$722.0K
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.ADD162,338$599.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

20 analysts
Buy 80% rate it Buy or better
Strong Buy6Buy10Hold4Sell0Strong Sell0
12-month targets · 11 analysts

Price is inside the target range. Median implies +64%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 25, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Aug 25, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Aug 19, 2026BMO Capital
INITIATE
INITIATEOutperform
Aug 10, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jun 29, 2026HC Wainwright & Co.
UPGRADE
UPGRADEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 5, 2026
Schenkein David P
Director
AWARD75,000 sh
Jun 5, 2026
NELSEN ROBERT
Director
AWARD75,000 sh
Jun 5, 2026
Kelly Michael Aaron
Director
AWARD75,000 sh
Jun 5, 2026
Foster-Cheek Kaye I
Director
AWARD75,000 sh
Jun 5, 2026
Chung Wendy
Director
AWARD75,000 sh
Jun 5, 2026
Cahill Thomas
Director
AWARD75,000 sh
Apr 16, 2026
Makhni Svetlana Ni
Chief Financial Officer
AWARD800,000 sh
Feb 26, 2026
Reine Allan
Chief Executive Officer
AWARD1,300,000 sh

Earnings setup

Estimates
Oct 30
reports in 3 days
−$0.23
EPS estimate, this quarter
−3%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.23-$0.28–-$0.19-1.0%$1.1M
Next Q-$0.22-$0.32–-$0.04-1.8%$6.5M
Current FY-$0.94-$1.11–-$0.81-1.1%$8.8M
Next FY-$0.89-$1.22–-$0.67-0.6%$10.6M
Reddit
Crowd this week 60° Warm 1 bullish · 0 bearish
Mentions, 7 days 1 0 in posts · 1 in comments
Recent comments
r/stocks Bullish 4d ago
I'm long PRME. Several of my biotech sources are really big into the name. The technology is fascinating.
All social signals and their track records

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 Press
Prime Medicine announced FDA clearance of its IND application for PM647, an in vivo Prime Editor for Alpha-1…
Impact 7/10
Sep 24, 2026 FDA
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver f
Aug 6, 2026 SEC
Prime Medicine reported Q2 2026 EPS of -$0.24, beating consensus of -$0.26 by 7.7%, with collaboration revenue of…
8-K — Impact 6/10
Jul 8, 2026 SEC
Prime Medicine won a binding arbitration against Beam Therapeutics, with the tribunal ruling that Prime's AATD…
8-K — Impact 6/10
Jun 30, 2026 Inst.
ARK Investment Management LLC — ADD
8,348,746 shares ($30.8M)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — DOUBLED
3,430,518 shares ($12.7M)
Jun 18, 2026 Press
Prime Medicine announced that New Zealand's Medsafe cleared its Clinical Trial Application for PM577a, an in vivo…
Impact 6/10
Jun 5, 2026 Insider
Schenkein David P was granted 75,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Oct 30, 2026
Earnings date
PRME Q3 2026 Earnings Scheduled — 2026-10-30
Recent
Sep 24, 2026
FDA
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory…
Aug 6, 2026
Earnings
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup…
Aug 6, 2026
Earnings date
PRME Q2 2026 Earnings Scheduled — 2026-08-06
Aug 5, 2026
Earnings date
PRME Q2 2026 Earnings Scheduled — 2026-08-05
Jun 18, 2026
FDA
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577a targets the H1069Q mutation in the ATP7B gene…

SecBot reports

5 filings · 3 press releases · 2 bullish · 2 bearish · 1 neutral
All PRME filing & press-release reports (8)